“We connect NK cells with tumor cells so they can destroy ... Innate Pharma’s therapies mark the dawn of a new generation of immunotherapy agents. “For the last 10 years, I think ...

Clinical data from Indaptus’ ongoing Phase 1 trial evaluating Decoy20 in advanced solid tumors.

NK cells are emerging as a potentially safer ... The company is also hopeful that its approach could extend the use of cell-based immunotherapy for cancer to solid tumours, something that has ...

Medicenna Therapeutics (MDNA) announced the presentation of new clinical data from its ongoing ABILITY-1 study evaluating MDNA11 alone or in ...

Discover how leveraging TLR7/8 agonists in combination with systemic IFN-I represents a promising strategy for treating melanoma.

To assess whether NK cells were involved in antitumor response generated by fasting, Delconte and her team depleted these ...

It is noted that the dysfunction of natural NK cells (cells of the innate immune system) is the main cause of the disease. At the same time, according to Alexander Kolsanov, Rector of SamSMU, ...

1Recourse Biology, Houston, TX.

Agenus Inc. (Nasdaq: AGEN), a leader in immuno-oncology, today presented data at the American Association for Cancer Research (AACR) IO Annual Meeting ...

Scientists have discovered a novel subset of cancer-fighting immune cells that reside outside ... Pitt and a member of the Cancer Immunology and Immunotherapy Program and Tumor Microenvironment ...

ImmunityBio, Inc. , a leading immunotherapy company, today announced the U.S. Food and Drug Administration (FDA) has authorized an expanded access program (EAP) that will bring a vital alternative ...